Diabetes UK Annual Professional Conference, Liverpool Phenotypic features of patients with Type 2 diabetes at increased risk of severe hypoglycemic events occurring before or after cardiovascular events
E Standl , SR Stevens , Y Lokhnygina , JB Buse , AP Maggioni , RJ Mentz , AF Hernandez and RR Holman
Diabetic Medicine 2019;36:Suppl 1:131 [Abstract]
American College of Cardiology (ACC) Annual Scientific Sessions, New Orleans Patients with diabetes and peripheral arterial disease: Results from the EXSCEL trial
Anish Badjatiya, Peter Merrill, John Buse, Shaun Goodman, Brian Katona, Nayyar Iqbal, Peter Ohman, Neha Pagidipati, Naveed Sattar, Rury Holman, Adrian Hernandez, Robert J. Mentz, Manesh Patel, Schuyler Jones
Journal of the American College of Cardiology 2019;73:9 (Suppl 1):2040 [Abstract]
American College of Cardiology (ACC) Annual Scientific Sessions, New Orleans Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established atherosclerotic cardiovascular disease: Insights from the TECOS study
Jay Shavadia, Yinggan Zheng, Jennifer B. Green, Paul Armstrong, Cynthia Westerhout, Darren McGuire, Matthew Roe, J. H. Cornel, Rury Holman, Eric D. Peterson
Journal of the American College of Cardiology 2019;73:9 (Suppl 1):138 [Abstract]
American College of Cardiology (ACC) Annual Scientific Sessions, New Orleans Increased risk of severe hypoglycemic events before and after cardiovascular events in type 2 diabetes: Validation of a novel concept
Eberhard Standl, Susanna Stevens, Yuliya Lokhnygina, John Buse, Aldo Maggioni, Robert Mentz, Ambady Ramachandran, Adrian Hernandez, Rury Holman
Journal of the American College of Cardiology 2019;73:9 (Suppl 1):24 [Abstract]
55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Risk factors for heart failure in the ACE trial population
C.A.B. Scott , J.J. McMurray, L. Rydén, Y. Sun, M. Tendera, R.L. Coleman, R.R. Holman
Diabetologia 2019;62:(Supp 1):S515 [Abstract]
55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Risk of microvascular complications over 30 years in latent autoimmune diabetes of adults compared with type 2 diabetes
E. Maddaloni, R.L. Coleman, O.F. Agbaje, R. Buzzetti, R.R. Holman
Diabetologia 2019;62:(Supp 1):S115 [Abstract]
55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance
S. Xu, C. Scott, R.L. Coleman, J. Tuomilehto, R.R. Holman
Diabetologia 2019;62:(Supp 1):S150 [Abstract]
55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Estimating cardiovascular risk and all-cause mortality in individuals with type 2 diabetes using the UKPDS Outcomes Model
R.L. Coleman, A.M. Gray, D.K. McGuire, R.R. Holman
Diabetologia 2019;62:(Supp 1):S152 [Abstract]
2018
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin Potential impact of differential drop-in of open-label diabetes medications in EXSCEL
J.B. Buse, M.A. Bethel, R.A. Patel, S.R. Stevens, S.M. Gustavson, Y. Lokhnygina, A.F. Hernandez, R.R.Holman, for the EXSCEL Study Group
Diabetologia 2018;61:(Suppl 1):S21-S22 [Abstract]
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
A.F. Hernandez, M.A. Bethel , G.L. Bakris , P. Merrill, S.M. Gustavson, B.G. Katona, P. Ohman, Y. Lokhnygina, R.J. Mentz, R.R. Holman
Diabetologia 2018;61:(Suppl 1):S38 [Abstract]
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
L. Mc Morrow, F. Becker, J. Leal, A.M. Gray, R. Coleman, H.C. Gerstein, L. Rydèn, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S344 [Abstract]
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
F. Becker, H.Dakin, S.D.Reed, Y.Li, J. Leal, S.M. Gustavson, B.Kartman, E.Wittbrodt, A.M. Gray, A.F.Hernandez, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S366 [Abstract]
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin Changes in serum calcitonin concentrations and incidence of adjudicated medullary thyroid carcinoma in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
B. Katona, M.A. Bethel, R. Patel, V.P. Thompson, S.M. Gustavson, P. Ohman, N. Iqbal, J.B.Buse, A.F. Hernandez, R.R.Holman
Diabetelogia 2018;61:(Suppl 1):S376 [Abstract]
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL
S.D. Reed, Y. Li, H. Dakin, F. Becker, J. Leal, S.M. Gustavson, B. Kartman, E. Wittbrodt, R.J. Mentz, N.J. Pagidipati, M.A. Bethel, A.M. Gray, R.R. Holman, A.F. Hernandez
Diabetelogia 2018;61:(Suppl 1):S426 [Abstract]
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin The effect of lixisenatide on post-prandial blood glucose and glucagon in type 1 diabetes
C. Ballav, A. Dhere, O. Agbaje, I. Kennedy, R.R. Holman, K.R. Owen
Diabetelogia 2018;61:(Suppl 1):S387 [Abstract]
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin Risk of cardiovascular disease in individuals with latent autoimmune diabetes of adults: results from the UKPDS
E. Maddaloni, R.L. Coleman, P. Pozzilli, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S574-5 [Abstract]
European Society of Cardiology (ESC) Congress 2018, Munich Effects of once weekly exenatide on clinical outcomes in the subgroup of patients with preexisting cardiovascular disease: insights from EXSCEL
R.J. Mentz, V.P. Thompson, S.M. Gustavson, N. Iqbal, P. Ohman, R.R. Holman, A.F. Hernandez
European Heart Journal 2018;39:(Suppl 1):1082 [Abstract]
European Society of Cardiology (ESC) Congress 2018, Munich LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS
G.M. De Ferrari, S.R. Stevens, G. Ambrosio, S. Leonard, D.K. McGuire, P.W. Armstrong, J.B. Green, M.A. Bethel, R.R. Holman, E.D. Peterson
European Heart Journal 2018;39:(Suppl 1):399-40 [Abstract]
European Society of Cardiology (ESC) Congress 2018, Munich Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine
A. Sharma, Y. Zheng, J.A. Ezekowitz, C.M. Westerhout, S.G. Goodman, P.W. Armstrong, J.B. Buse, J.B. Green, K.D. Kaufman, D.K. McGuire, G. Ambrosio, L.M. Chuang, R.D. Lopes, E.D. Peterson, R.R. Holman
European Heart Journal 2018;39:(Suppl 1):871 [Abstract]
American Diabetes Association (ADA) Conference, Orlando Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
M. ANGELYN BETHEL, ROBERT J. MENTZ, PETER MERRILL, JOHN B. BUSE, JULIANA C. CHAN, SHAUN G. GOODMAN, NAYYAR IQBAL, NELI JAKUBONIENE, BRIAN G. KATONA, YULIYA LOKHNYGINA, RENATO D. LOPES, ALDO P. MAGGIONI, PETER K. OHMAN, NEIL R. POULTER, AMBADY RAMACHANDRAN, TSVETALINA TANKOVA, BERNARD ZINMAN, ADRIAN F. HERNANDEZ, RURY R. HOLMAN
Diabetes 2018;67:(Suppl 1):522-P [Abstract]
American Diabetes Association (ADA) Conference, Orlando EXSCEL-Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus
SHELBY D. REED, YANHONG LI, HELEN A. DAKIN, FRAUKE BECKER, JOSE LEAL, STEPHANIE GUSTAVSON, BERNT KARTMAN, ERIC T. WITTBRODT, ROBERT J. MENTZ, NEHA PAGIDIPATI, M. ANGELYN BETHEL, ALASTAIR M. GRAY, RURY R. HOLMAN and ADRIAN F. HERNANDEZ
Diabetes 2018;67:(Suppl 1):1319-P [Abstract]
American Diabetes Association (ADA) Conference, Orlando Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group
LINDSAY CLEGG, HIDDO L. HEERSPINK, ROBERT C PENLAND, WEIFENG TANG, DAVID W BOULTON, SRINIVAS BACHINA, ROBERT D FOX, PETER FENICI, MARCUS THURESSON, ROBERT J MENTZ, ADRIAN F HERNANDEZ, M ANGELYN BETHEL, RURY R HOLMAN
Diabetes 2018;67:(Suppl 1):130-LB [Abstract]
American Diabetes Association (ADA) Conference, Orlando Cardiovascular Event Hazards over Time in TECOS
M. ANGELYN BETHEL, HARALD SOURIJ, SUSANNA R. STEVENS, YULIYA LOKHNYGINA, RENATO D. LOPES, AMANDA ADLER, DARREN K. MCGUIRE, ERIC PETERSON and RURY R. HOLMAN
Diabetes 2018;67:(Suppl 1):452-P [Abstract]
American Diabetes Association (ADA) Conference, Orlando Regional Variations in Case Fatality following a Major Coronary or Cerebrovascular Event in People with Type 2 Diabetes-Evidence from the ADVANCE Trial and TECOS Trial
PHILIP M. CLARKE, XINYANG HUA, JOHN CHALMERS, MARK WOODWARD, ESQ., RUTH L. COLEMAN, JENNIFER B. GREEN, DARREN K. MCGUIRE, RURY R. HOLMAN
Diabetes 2018;67:(Suppl 1):1299-P [Abstract]
Diabetes Congress of the German Diabetes Association, Berlin Effects of exenatide on cardiovascular outcomes in patients with type 2 diabetes mellitus: results of the EXSCEL study
Hanefeld M on behalf of EXSCEL Study Group
Diabetology and Metabolism 2018;13:Suppl 1:S70 [Abstract]
14th National Conference of the Primary Care Diabetes Society, Birmingham Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: Insights from EXSCEL
Mentz RJ, on behalf of the EXSCEL Study Group
Diabetes and Primary Care 2018;20:Suppl A:3 [Abstract]
2017
Diabetes UK Annual Professional Conference, Manchester Sensing hypoglycaemia at an earlier stage using an integrated physiological multi-signal data fusion approach
MJ Theodorakis, D Clifton, GW Colopy, J Jorge, A Dhere, C Ballav, I Kennedy, O Agbaje, L Tarassenko, RR Holman
Diabetic Medicine 2017;34 (Suppl 1):62-63 [Abstract]
Diabetes UK Annual Professional Conference, Manchester Development of an online risk calculator to predict durability of good glycaemic control with sulfonylurea and thiazolidinedione therapy: a MASTERMIND stratified medicine study
JM Dennis, WE Henley, M Weedon, M Lonergan, AG Jones, N Sattar, RR Holman, ER Pearson, AT Hattersley, BM Shields and LR Rodgers
Diabetic Medicine 2017;34 (Suppl 1):5 - 35 [Abstract]
Diabetes UK Annual Professional Conference, Manchester Predictors of response to SGLT2-inhibitors and DPP4-inhibitors: a MASTERMIND stratified medicine study
B Shields, J Dennis, W Henley, M Weedon, M Lonergan, A Jones, N Sattar, R Holman, E Pearson and A Hattersley
Diabetic Medicine 2017;34 (Suppl 1):5 - 35 [Abstract]
Diabetes UK Annual Professional Conference, Manchester Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
RL Coleman, A Gray, UC Broedl, D Fitchett, JT George, HJ Woerle, B Zinman and RR Holman
Diabetic Medicine 2017;34 (Suppl 1):5 - 35 [Abstract]
Diabetes UK Annual Professional Conference, Manchester Estimating the potential incremental benefits on Type 2 diabetes complications rates of targeting successively lower LDL-cholesterol levels
SA Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman and MA Bethel
Diabetic Medicine 2017;34 (Suppl 1):36-194 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS)
S.S. Engel, M.A. Bethel, J. Garg, S.R. Stevens, Y. Lokhnygina3, R.G. Josse4, J.B. Green, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S3 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
O.F. Agbaje, R.L. Coleman, A.T. Hattersley, E.Z. Pearson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S300 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Risk of anaemia with long-term metformin use in a community setting
L.A. Donnelly, K. Gardner, R.L. Coleman, N. Sattar, A.T. Hattersley, R.R. Holman, E.R. Pearson
Diabetelogia 2017;60:(Suppl 1):S139 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Associations between insulin dose titration over one year and hypoglycaemia: a descriptive study using 4-T data
A.J. Farmer, M.-M. Lee , J. Oke , A. Reutens , J. Shaw , R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S310 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon No major impact seen with sitagliptin on rates of cardiovascular death or hospitalisation for heart failure following myocardial infarction during TECOS
M.A. Nauck, K.S. Pieper, Y. Lokhnygina, D.K. McGuire, E.D. Peterson, R.R. Holman,
Diabetelogia 2017;60:(Suppl 1):S356 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Association between race and glycaemic response to sitagliptin: insights from TECOS
T.M.E. Davis, H. Mulder, Y. Lokhnygina, E. Standl, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S356 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
A.M. Gray, J. Leal, S.D.Reed, Y. Li, F. Graham, J.B.Green, K.D. Kaufman, L. Radican, J. Alfredsson, J. Buse, A. Riefflin, F. Van de Werf, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S357 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon A calculator to predict durability of HbA1c response with DPP4 inhibitors, sulfonylureas and thiazolidinediones: a MASTERMIND precision medicine study
J.M. Dennis, W.E. Henley, M.N. Weedon, M. Lonergan, L.R. Rodgers, A.G. Jones, N.A. Sattar, R.R. Holman, E.R. Pearson, A.T. Hattersley, B.M. Shields
Diabetelogia 2017;60:(Suppl 1):S388 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Predictors of response to SGLT2-inhibitors and DPP4-inhibitors
B.M. Shields, J. Dennis, W. Henley, M.Weedon, M. Lonergan, L. Rodgers, A. Jones, N. Sattar, R. Holman, E. Pearson, A. Hattersley
Diabetelogia 2017;60:(Suppl 1):S404 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
R.L. Coleman, A.M. Gray, U.C. Broedl, D. Fitchett, J.T. George, H.-J. Woerle, B. Zinman, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S522 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Modelling incremental benefits on macro- and micro-vascular complications rates when targeting lower systolic blood pressure levels in type 2 diabetes
S.A. Mostafa, R.L. Coleman, O.F. Agbaje, A. Gray, R.R. Holman, M.A. Bethel
Diabetelogia 2017;60:(Suppl 1):S525 [Abstract]
American Heart Association (AHA) Scientific Sessions 2017, Anaheim Underuse of Oral Anticoagulation, High Use of Aspirin and Worse Clinical Outcomes in Patients With Type 2 Diabetes and Atrial Fibrillation: Insights From the TECOS Trial
Patricia Guimaraes, Renato D Lopes, Susanna R Stevens, Jennifer B Green, Darren K McGuire, Rury R Holman and Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;136:Supp 1: [Abstract]
American Heart Association (AHA) Scientific Sessions 2017, Anaheim International Variation in Management and Clinical Outcome of Patients With Type 2 Diabetes and Heart Failure: Insights From TECOS
Ankeet S Bhatt, Nancy Luo, Nicole Solomon, Neha J Pagidipati, Giuseppe Ambrosio, Jennifer B Green, Darren K McGuire, Eberhard Standl, Jan H Cornel, Sigrun Halvorsen, Renato D Lopes, Harvey White, Rury R Holman, Eric D Peterson, and Robert J Mentz, on behalf of the TECOS Study Group
Circulation 2017;136:Suppl 1: [Abstract]
American Heart Association (AHA) Scientific Sessions 2017, Anaheim Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial
Robert J Mentz, M. Angelyn Bethel, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Julian C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Steven P Marso, Peter Öhman, Neha J Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Rury R Holman, Adrian F Hernandez, on behalf of the EXSCEL Study Group
Circulation 2017;136:24: [Abstract]
Association of British Clinical Diabetologists (ABCD) Autumn Meeting 2016, Brighton Estimating the potential risk reduction of Type 2 diabetes mellitus (T2DM) complications if systolic blood pressure (SBP) targets were to be lowered
S Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman, MA Bethel
The British Journal of Diabetes 2017;17:1:42 [Abstract]
Quality of Care and Outcomes Research (QCOR) Scientific Sessions 2017, Arlington Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial
Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, Jennifer B Green, M. A Bethel, Paul W Armstrong, Robert G Josse, Darren K McGuire, Yuliya Lokhnygina, Jan H Cornel, Sigrun Halvorsen, Timo E Strandberg, Tuncay Delibasi, Rury R Holman, Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;10:Suppl 3: [Abstract]
European Society of Cardiology (ESC) Congress 2017, Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial
Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, Jennifer B Green, M. A Bethel, Paul W Armstrong, Robert G Josse, Darren K McGuire, Yuliya Lokhnygina, Jan H Cornel, Sigrun Halvorsen, Timo E Strandberg, Tuncay Delibasi, Rury R Holman, and Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;10:Suppl 3: [Abstract]
Francophone Society of Diabetes Annual Congress 2017, Lille Evaluation of the Safety Profile of Sitagliptin in Older Adults in the TECOS Cardiovascular Safety Trial
Angelyn Bethel, Samuel Engel, Jennifer Green, Zhen Huang, Keith Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Eric Peterson, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A55-A56
Francophone Society of Diabetes Annual Congress 2017, Lille Impact on cardiovascular events and tolerance of sitagliptin in insulin-treated patients with type 2 diabetes: the TECOS experiment
Angelyn Bethel, Sam Engel, Jie Ding, Robert Josse, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A56
Francophone Society of Diabetes Annual Congress 2017, Lille Differences Between Men and Women in the Cardiovascular Safety Test of Sitagliptin (TECOS)
Jennifer Green, Joakim Alfredsson, Susanna Stevens, Shelby Reed, Darren McGuire, Paul Armstrong, Sam Engel, Angelyn Bethel, Frans Van de Werf, Eric Peterson, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A56
American Diabetes Association (ADA) Conference, San Diego-P Medical Resource Use and Costs in Patients with Type 2 Diabetes Mellitus during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SHELBY D. REED, YANHONG LI, JOSE LEAL, FELICIA GRAHAM, JOAKIM ALFREDSSON, ALASTAIR M. GRAY, JOHN B. BUSE, JENNIFER B. GREEN, KEITH D. KAUFMAN, AXEL RIEFFLIN, SHAILAJA SURYAWANSHI, FRANS VAN DE WERF, ERIC D. PETERSON, RURY R. HOLMAN, TECOS STUDY GROUP
Diabetes 2017;66:(Suppl 1):A697-A750. [Abstract]
American Diabetes Association (ADA) Conference, San Diego Time to Insulin in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M A BETHEL, SAMUEL S ENGEL, JYOTSNA GARG, SUSANNA R STEVENS, YULIYA LOKHNYGINA, ROBERT G JOSSE, JENNIFER B GREEN, ERIC D PETERSON, RURY R HOLMAN, TECOS STUDY GROUP
Diabetes 2017;66:(Suppl 1):1183-P [Abstract]
American Diabetes Association (ADA) Conference, San Diego Emerging Sitagliptin Benefit for All-Cause Hospitalizations: Evidence from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SHELBY D REED, YANHONG LI, JOSE LEAL, FELICIA GRAHAM, JOAKIM ALFREDSSON, ALASTAIR M GRAY, JOHN B BUSE, JENNIFER B GREEN, KEITH D KAUFMAN, AXEL RIEFFLIN, SHAILAJA SURYAWANSHI, FRANS VAN DE WERF, ERIC D PETERSON, RURY R HOLMAN, FOR THE TECOS STUDY
Diabetes 2017;66:(Suppl 1):1344-P
2016
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial
R.G. Josse, S.R. Majumdar, Y. Zheng, J.B. Buse, J.B. Green, K.D. Kaufman, E.D. Peterson, R.R.Holman, P.W. Armstrong, on behalf of the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S372 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Impact of sitagliptin on cardiovascular and safety-related outcomes in insulin-treated type 2 diabetes: the TECOS experience
M.A. Bethel, S.S. Engel, J. Ding, R.G. Josse, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S369 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabete, Munich Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
S.S. Engel, S. Suryawanshi, R.G. Josse, E.D. Peterson, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S361 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Stimulatory effects of the long - acting kisspeptin analogue TAK - 448 on serum testosterone in men with type 2 diabetes and hypogonadotropic hypogonadism
J.T. George, J.E. Milton, A.E. Cooper, S. Greentree, R.A. Anderson and R.R. Holman
Diabetologia 2016;59:Suppl 1:S228-S229 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Estimated 10-year benefit for diabetes complication rates by 1% HbA1c decrements in people with type 2 diabetes and cardiovascular disease
S.A. Mostafa, R.R. Holman, R.L. Coleman, O. Agbaje, M.A. Bethel
Diabetologia 2016;59:Suppl 1:S543 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
J.B. Green, J. Alfredsson, S.R. Stevens, S.D. Reed, D.K. McGuire, P.W. Armstrong, S.S. Engel, M.A. Bethel, F. Van de Werf, E.D. Peterson, R.R. Holman
Diabetologia 2016;59:Suppl 1:S544 [Abstract]
American Heart Association (AHA) Scientific Sessions 2016, New Orleans Treated Systolic Blood Pressure and Cardiovascular Risk in Adults With Hypertension and Type 2 Diabetes: Results From the TECOS Trial
Ann M Navar, Dianne S Gallup, Yuliya Lokhnygina, Jennifer B Green, Darren K McGuire, Paul W Armstrong, John B Buse, Samuel S Engel, John M Lachin, Eberhard Standl, Frans Van de Werf, Rury R Holman, and Eric D Peterson
Circulation 2016;134:Suppl 1: [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Stratification using gender and body mass index (BMI) results in better glycaemic control for longer: a MASTERMIND study
B Shields, J Dennis, L Rodgers, A Jones, M Lonergan, W Henley, R Holman, E Pearson, A Hattersley, and the MASTERMIND Consortium
Diabetic Medicine 2016;33:Suppl 1:10-11 [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin
MA Bethel, SS Engel, JB Green, Z Huang, KD Kaufman,E Standl, S Suryawanshi, F Van de Werf, ED Peterson, and RR Holman
Diabetic Medicine 2016;33:Suppl 1:86 [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Personalisation of treatment with metformin by age, weight and sex: a MASTERMIND study
ME Lonergan, B Shields, OF Agbaje, J Dennis, M Weeden, L Rodgers, RR Holman, A Hattersley and EW Pearson
Diabetic Medicine 2016;33:Suppl 1:194 [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Baseline Characteristics of Patients Enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
ROBERT MENTZ, M ANGELYN BETHEL, STEPHANIE GUSTAVSON, VIVIAN THOMPSON, JOHN B BUSE, JULIANA CHAN, ALDO P MAGGIONI, STEVEN P MARSO, PETER OHMAN, NEIL POULTER, AMBADY RAMACHANDRAN, BERNARD ZINMAN, NAYYAR IQBAL, ADRIAN F HERNANDEZ, RURY R HOLMAN
Diabetes 2016;65:(Suppl 1):1039-P [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Assessing the Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SAMUEL S ENGEL, SHAILAJA SURYAWANSHI, ROBERT G JOSSE, ERIC PETERSON, RURY R HOLMAN, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):1181-P [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Personalizing Therapy in Type 2 Diabetes: The Effect of BMI and Gender on Response and Side Effects to Sulfonylureas and Thiazolidinediones Itinerary
JOHN M DENNIS, WILLIAM E HENLEY, MICHAEL N WEEDON, MICHAEL LONERGAN, LAUREN R RODGERS, ANGUS G JONES, RURY R HOLMAN, EWAN R PEARSON, ANDREW T HATTERSLEY, BEVERLEY M SHIELDS
Diabetes 2016;65:(Suppl 1):1541-P [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial
ROBERT G JOSSE, SUMIT R MAJUMDAR, JOHN B BUSE, JENNIFER B GREEN, KEITH D KAUFMAN, CYNTHIA M WESTERHOUT, YINGGAN ZHENG, ERIC PETERSON, RURY R HOLMAN, PAUL W ARMSTRONG, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):587-P [Abstract]
2015
American Diabetes Association (ADA) Conference, Boston Reductions in hemoglobin and packed cell volume over 3 years in UKPDS patients with newly-diagnosed type 2 diabetes
Ruth L. Colman, Rury R. Holman
Diabetes 2015;64:1:A440
51st Annual Meeting of the European Association for the Study of Diabetes, Stockholm Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus
N. Sattar, D. Preiss , D. Blom , C.S. Djedjos, M. Elliott , A. Pellacani, S.M. Wasserman, M. Koren, R. Holman
Diabetelogia 2015;58:(Suppl 1):S79 [Abstract]
51st Annual Meeting of the European Association for the Study of Diabetes, Stockholm Patient characteristics are associated with treatment response to second line glucose lowering therapy: a MASTERMIND study
B.M. Shields, M. Lonergan, J. Dennis, A. Jones, L. Rogers, M. Weedon, L. Donnelly, R. Holman, W. Henley, E. Pearson, A. Hattersley
Diabetelogia 2015;58:(Suppl 1):S405 [Abstract]
2014
American Diabetes Association (ADA) Conference, San Diego Effects of Long-term, Monthly Administration of the PCSK9 Inhibitor Evolocumab in Patients with Dysglycemia or Metabolic Syndrome
Robert R. Henry, Rury R. Holman, Robert P. Giugliano, Frederick J. Raal, David Sullivan, Nariman Honarpour, Patric Nelson, Mary Elliott, Thomas Liu, Scott M. Wasserman, Michael J. Koren
Diabetes Care 2014;63 supp 1:A157
2012
American Diabetes Association (ADA) Conference, Philadelphia Positive Impact of Revised FDA Guidance on Clinical Trial Design in Diabetes
Bethel MA, Sourij H
Diabetes 2012;61:Supp 1:A264 [Abstract]
American Diabetes Association (ADA) Conference, Philadelphia Updated UKPDS Risk Engine that Estimates Primary and Secondary Cardiovascular Disease Risk in People With Recently-Diagnosed or Established Type 2 Diabetes
Coleman RL, Stevens RJ, Holman RR
Diabetes 2012;61:Supp 1:A103 [Abstract]
15th International & 14th European Congress of Endocrinology, Florence Time course of the glucose legacy effect
R. Holman
Endocrine Abstracts 2012;29:S9.3
Diabetes UK Annual Professional Conference, Glasgow A self-administered oral glucose tolerance test
MA Bethel, H Sourij, S White, L Tucker, I Kennedy, R Coleman, A Ring and RR Holman
Diabetic Medicine 2012;2012 Sup 1:47 [Abstract]
2011
39th Meeting of the British Society for Paediatric Endocrinology and Diabetes, London Early intervention in type 2 diabetes mellitus
Rury Holman
Endocrine Abstracts 2011;27:S22
2010
Diabetes UK Annual Professional Conference, Liverpool Challenges of Treating to Target - Experiences and views of patients and staff participating in the three-year 4-T trial
J Lawton, N Jenkins, A Farmer, N Hallowell, RR Holman
Diabetic Medicine 2010;27 Supp 1:21 [Abstract]
2009
Diabetes UK Annual Professional Conference, Glasgow Addition of exenatide therapy to insulin treatment in individuals with type 2 diabetes
Price HC, Holman RR, Levy JC, Ayyagari U.
Diabetic Medicine 2009;26:Suppl 1:141 [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Addition of Exenatide therapy to oral blood glucose lowering treatment in individuals with Type 2 diabetes
Ayyagari U, Holman RR, Levy JC, Price HC
Diabetic Medicine 2009;26:Suppl 1:141 [Abstract]
69th Scientific Session of the American Diabetes Association, New Orleans Unravelling the Dynamics of Insulin Dose and Changes in Weight and HbA1c
Paul SK, Holman RR
Diabetes 2009;58:Suppl 1:A163 [Abstract]
69th Scientific Session of the American Diabetes Association, New Orleans Rationale and Design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Bethel MA, Green J, Califf RM, Holman RR
Diabetes 2009;59:Suppl 1:A555 [Abstract]
69th Scientific Session of the American Diabetes Association, New Orleans Physical Activity in Adults at High Risk of Cardiovascular Disease
Price HC, Griffin SJ, Holman RR
Diabetes 2009;58:Suppl 1:A587 [Abstract]
69th Scientific Session of the American Diabetes Association, New Orleans Prevalence of Undiagnosed Dysglycaemia in Adults at High Risk of Cardiovascular Disease
Price HC, Griffin SJ, Holman RR
Diabetes 2009;58:Suppl 1:A639 [Abstract]
69th Scientific Session of the American Diabetes Association, New Orleans Differences in Insulin Treatment Satisfaction Following Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Farmer AJ, Oke J, Stevens R, Holman RR
Diabetes 2009;58:Suppl 1:A130 [Abstract]
69th Scientific Session of the American Diabetes Association, New Orleans Do Glycoalbumin Levels Preferentially Reflect Postprandial Glucose Excursions?
Hartweg J, Paul SJ, Fisher K, Carter R, Klyne R, Holman RR
Diabetes 2009;58:Suppl 1:A505 [Abstract]
2008
Diabetes UK Annual Professional Conference, Glasgow The UKPDS Life Expectancy Calculator for Individuals with Type 2 diabetes
Price HC, Kennedy I, Clarke PM, Gray AM and Holman RR.
Diabetic Medicine 2008;25:suppl 1:63 [Abstract]
68th Scientific Session of the American Diabetes Association, San Francisco European physicians overestimate life expectancy and the likely impact of interventions in individuals with type 2 diabetes
Price HC, Thorne KI, Dukát A and Kellett J
Diabetes 2008;57:(Suppl 1):A181 [Abstract]
44th Annual Meeting of the European Association for the Study of Diabetes, Rome Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, Griffin SJ
Diabetologia 2008;51:Suppl 1:S549 [Abstract]
44th Annual Meeting of the European Association for the Study of Diabetes, Rome Characteristics of patients requiring planned modification to regimen allocation during the first year of the 4-T Trial: need for twice-daily basal insulin or addition of a second insulin formulation
Levy JC, Farmer AJ, Thorne KI, Paul SK, Darbyshire JL, Davies MJ, Holman RR
Diabetologia 2008;51:Suppl 1:S387 [Abstract]
68th Scientific Session of the American Diabetes Association, San Francisco Continuous Glucose Monitoring Results from the Treating to Target in Type 2 Diabetes (4-T) Trial
Davies MJ, Levy JC, Thorne KI, Paul SK, Darbyshire JL, Holman RR.
Diabetes 2008;57:(Suppl 1):A12 [Abstract]
International Biometric Conference, Dublin A Generalized Autoregressive Conditional Heteroscedasticity Model (GARCH) to Analyze Continuous Blood Glucose Monitoring Data for Diabetic Patients
Sanjoy PK, Holman RR
International Biometric Society 2008;978-0-9821919-0-3 [Abstract]
International Biometric Conference, Dublin Statistical Analysis of 8-Point Self Measured Capillary Glucose Profiles in Type 2 Diabetic Patients to Compare the Efficacy of Three Different Insulin Regimens
Paul SK, Thorne KI, Holman RR
International Biometric Society 2008;978-0-9821919-0-3 [Abstract]
2007
2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona Does metformin prevent cardiovascular events?
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S26 [Abstract]
2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona Abdominal obesity, metabolic syndrome and global cardiometabolic risk
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S37 [Abstract]
2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona A new era in the secondary prevention of CVD in prediabetes - the Acarbose Cardiovascular Evaluation (ACE) trial
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S40 [Abstract]
2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona The expanding evidence base - what have we added to our understanding of diabetes disease modification?
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S43-S44 [Abstract]
2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona Acarbose Cardiovascular Evaluation (ACE) Trial in prediabetic subjects
Holman RR, Pan CY
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S128 [Abstract]
67th Scientific Session of the American Diabetes Association, Chicago The Oxford Risk Engine: A Cardiovascular Risk Calculator for Individuals with or without Type 2 diabetes
Coleman RL, Stevens RJ, Holman RR
Diabetes 2007;56:Suppl 1:A170 [Abstract]
The Diabetes UK Annual Professional Conference, Glasgow Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine
Coleman RL, Stevens RJ, Holman RR
Diabetic Medicine 2007;24:Suppl 1:56 [Abstract]
67th Scientific Session of the American Diabetes Association, Chicago Life-expectancy in Individuals with Type 2 Diabetes: Implications for Annuities.
Price HC, Cull CA, Clarke PM, Gray AM and Holman RR
Diabetes 2007;56:Suppl 1:A596 [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Framingham Equations Underestimate Cardiovascular Risk Compared with the UKPDS Risk Engine in People with Type 2 Diabetes.
Price HC, Cull CA, Coleman RL, Stevens RJ and Holman RR
Diabetic Medicine 2007;24:suppl 1:55 [Abstract]
28th Annual Conference of the International Society for Clinical Biostatistics, Alexandroupolis Modelling Continuous Glucose Monitoring Data: A Statistical Challenge
Paul SK, Holman RR
ISCB Abstracts 2007;117 [Abstract]
43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam Are measures of adiposity associated independently with incident cardiovascular disease in individuals with newly diagnosed type 2 diabetes?
Coleman RL, Holman RR
Diabetologia 2007;50:Suppl 1:S502 [Abstract]
43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam Increased incidence of fractures in women who received rosiglitazone in ADOPT (A Diabetes Outcome Progression Trial)
Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group
Diabetologia 2007;50:Suppl 1:S37 [Abstract]
43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain
Haffner SM, Kahn SE, Zinman B, Holman R, Viberti GF, Herman WH, Lachin JM, Kravitz BG, Heise MA
Diabetologia 2007;50:Suppl 1:S36 [Abstract]
43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam The distribution of macular hard exudates is related to future visual acuity in subjects with type 2 diabetes
Stratton IM, Scanlon PH, Holman RR, Stirling RJ, Lipinsk HL, Aldington SJ
Diabetologia 2007;50:Suppl 1:S99 [Abstract]
43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam Prevalence of glucokinase (GCK) mutations in people with elevated fasting glucose levels: implications for clinical trials
Gloyn AL, van de Bunt M, Stratton I, Tucker L, Lonie L, Ellard S, Holman RR
Diabetologia 2007;50:Suppl 1:S168 [Abstract]
43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam Determinants of monotherapy failure in ADOPT (A Diabetes Outcome Progression Trial)
Holman RR, Kahn SE, S. Haffner M, Zinman B, Viberti GF, Herman WH, Lachin JM, Kravitz BG, Heise MA
Diabetologia 2007;50:Suppl 1:S356 [Abstract]
43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes
Herman WH, Haffner SM, Kahn SE, Zinman B, Holman RR, Viberti GF, Lachin JM, Kravitz BG, Heise MA
Diabetologia 2007;50:Suppl 1:S362 [Abstract]
2006
Diabetes UK Annual Professional Conference, Birmingham Estimating risk of clinically evident neuropathy in type 2 diabetes: a UKPDS risk equation
Coleman RL, Stevens RJ, Holman RR
Diabetic Medicine 2006;23:Suppl. 2:51
66th Scientific Session of the American Diabetes Association, Washington Estimating Risk of Clinically Evident Retinopathy in Type 2 Diabetes.
Coleman RL, Stevens RJ, Aldington SJ, Holman RR
Diabetes 2006;55:Suppl 1:A53
27th Annual Conference of The International Society for Clinical Biostatistics, Geneva Nonparametric regression techniques for inference in highly skewed quality of life data - a case study with LDS diabetes patients using sf-36 scores
Paul SK, Holman RR
ISCB2006 Abstract Book 2006;215
Diabetes UK Annual Professional Conference, Birmingham Treating to target in Type 2 diabetes (4-T) study of analogue insulin initiation and titration
Farmer AJ, Thorne KA, Stratton IM, Davies M, Keenan J, Teo E, Levy J, Holman RR
Diabetic Medicine 2006;23:Suppl 2:85 [Abstract]
Diabetes UK Annual Professional Conference, Birmingham LDL cholesterol levels alone do not adequately assess coronary heart disease risk in Type 2 diabetes
Farmer AJ, Paul S, Stratton IM, Tucker L, Neil HAW, Holman RR
Diabetic Medicine 2006;23:Suppl 2:89 [Abstract]
66th Scientific Session of the American Diabetes Association, Washington LDL Cholesterol Level Alone does not Assess Coronary Heart Disease Risk Adequately in Type 2 Diabetes
Farmer AJ, Paul SK, Stratton IM, Tucker L, Neil AW and Holman RR
Diabetes 2006;55:Suppl 1:A462 [Abstract]
2005
41st Annual Meeting of the European Association for the Study of Diabetes, Athens Obesity is a major determinant of the association of C-reactive protein levels with the number of metabolic syndrome components in recently diagnosed, drug-naive type 2 diabetes: the ADOPT study cohort
Kahn SE, Zinman B, Viberti G, Kravitz BG, Yu D, Heise MA, Freed MI, the ADOPT Study Group
Diabetologia 2005;48:suppl 1:A249 [Abstract]
41st Annual Meeting of the European Association for the Study of Diabetes, Athens BMI and ratio of triglycerides to HDL are most predictive of insulin resistance in a drug naive population with type 2 diabetes
Patwardhan R, Lin X, Zambanini A, Eslava S, the ADOPT Study Group
Diabetologia 2005;48:suppl 1:A222 [Abstract]
65th Scientific Sessions of the American Diabetes Association, San Diego Hepatic enzymes are associated with insulin resistance and impaired fibrinolysis in drug naïve, recently diagnosed type 2 diabetes subjects
Haffner SM, Kahn SE, Heise MA, O'Neill MC, Zinman B, the ADOPT Study Group
Diabetes 2005;54:suppl 1:A255 [Abstract]
65th Scientific Sessions of the American Diabetes Association, San Diego Obesity is a major determinant of the association of C-reactive protein levels with the number of metabolic syndrome components in type 2 diabetes
Kahn SE, Zinman B, Viberti G, Kravitz BG, Yu D, Heise MA, Freed MI, the ADOPT Study Group
Diabetes 2005;54:suppl 1:A255 [Abstract]
65th Scientific Sessions of the American Diabetes Association, San Diego A Cardiovascular Risk Calculator for Type 2 Diabetes
Coleman RL, Stevens RJ, Matthews DR, Holman RR
Diabetes 2005;54:Suppl 1:A172
41st Annual Meeting of the European Association for the Study of Diabetes, Athens Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
Coleman RL, Stevens RJ, Holman RR
Diabetologia 2005;48:Suppl 1:A32
41st Annual Meeting of the European Association for the Study of Diabetes, Athens FPG and HbA1c are independent risk factors for microvascular but not macrovascular complications in newly diagnosed type 2 diabetes
Kim JI, Stevens RJ, Holman RR
Diabetologia 2005;48:Suppl 1:A33 [Abstract]
41st Annual Meeting of the European Association for the Study of Diabetes, Athens Susceptibility for latent autoimmune diabetes in adults (LADA) is determined by variation at the IDDM2 (insulin-gene) locus in white Caucasian patients from UK repositories
Desai M, Zeggini E, Owen KR, Holman RR, Levy JC, Hattersley AT, Hitman GA, Walker M, McCarthy MI, Clark A
Diabetologia 2005;48:Suppl1:A86 [Abstract]
41st Annual Meeting of the European Association for the Study of Diabetes, Athens Relationship of autoantibodies to glutamic acid decarboxylase (GADA) to deterioration of glycamic control assessed by therapy progression in latent autoimmune diabetes in adults (LADA) in the UKPDS
Clark A, Desai M, Cull CA, Horton VA, Christie MR, Bingley PJ, Bonifacio E, Levy JC, Holman RR
Diabetologia 2005;48:Suppl 1:A86 [Abstract]
41st Annual Meeting of the European Association for the Study of Diabetes, Athens Genotype and beta cell response to therapy in a large type 2 diabetic cohort
Powell BL, Stratton IM, Holman RR, McCarthy MI
Diabetologia 2005;48:Suppl 1:A101-A102 [Abstract]
Diabetes UK Annual Professional Conference, Glasgow AFORRD: a multi-centre trial evaluating potential cardiovascular risk reduction in patients with type 2 diabetes randomised in a factorial design to atorvastatin and/or omega-3 polyunsaturated fatty acids
Farmer AJ,Neil HAW, Holman RR
Diabetic Medicine 2005;22:S2:63 [Abstract]
2004
40th Annual Meeting of the European Association for the Study of Diabetes, Munich Evaluating SCORE and Framingham fatal coronary heart disease risk equations using UKPDS data
Coleman RL, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A42
40th Annual Meeting of the European Association for the Study of Diabetes, Munich Could non-HDL cholesterol replace total/HDL cholesterol ratio to estimate coronary heart disease risk in the UKPDS risk engine?
Stevens RJ, Coleman RL, Shine BL, Holman RR
Diabetologia 2004;47:Suppl 1:A61 [Abstract]
40th Annual Meeting of the European Association for the Study of Diabetes, Munich Risk factors for neuropathy in UKPDS
Stratton IM, Holman RR, Boulton AJM
Diabetologia 2004;47:Suppl 1:A47 [Abstract]
40th Annual Meeting of the European Association for the Study of Diabetes, Munich The haemoglobin glycation index is reproducible in dysglycaemic individual but is not explained by post-challenge plasma glucose levels
Kim JI, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A122 [Abstract]
40th Annual Meeting of the European Association for the Study of Diabetes, Munich GAD65 autoantibody titres at diagnosis in Latent Autoimmune Diabetes in Adults (LADA) differ from Type 1 diabetes (T1D) and together with epitope specificity predict insulin requirement
Desai M, Williams AJK, Horton VA, Bingley PJ, Levy JC, Cull CA, Holman RR, Bonifacio E, Christie MR, Clark A
Diabetologia 2004;47:Suppl 1:A186 [Abstract]
40th Annual Meeting of the European Association for the Study of Diabetes, Munich Cost utility analysis of intensive blood-glucose control, tight blood pressure control and metformin in patients with Type 2 diabetes
Clarke PM, Gray A, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A50 [Abstract]
40th Annual Meeting of the European Association for the Study of Diabetes, Munich A calculator for HOMA
Holman RR, Hines G, Kennedy I, Stevens RJ, Matthews D, Levy JC
Diabetologia 2004;47:Suppl 1:A222 [Abstract]
2003
18th International Diabetes Federation Congress, Paris Estimations of the clinical benefit of optimal blood glucose, blood pressure and lipid control in type 2 diabetic patients with the metabolic syndrome
Koro CE, Bowlin S, Sun Y, Gomez-Camineros A, the ADOPT Study Group
Diabetologia 2003;46:Suppl 2:A76 [Abstract]
18th International Diabetes Federation Congress, Paris Differences in the prevalence of the metabolic syndrome between ethnic groups in recently diagnosed type 2 diabetes in the North American cohort of the ADOPT study
Haffner SM, Zinman B, Kahn SE, Herman WH, Heise MA, O'Neill MC, Porter LE, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A144 [Abstract]
18th International Diabetes Federation Congress, Paris Symptoms and health status in a recently-diagnosed type 2 diabetic population: the ADOPT study
Perry A, Herman W, Freed MI, Heise MA, Kravitz B, the ADOPT Study Group
Diabetes Metabolism 2003;29:4S16-4S17 [Abstract]
18th International Diabetes Federation Congress, Paris Are different clinical practice guidelines associated with regional differences in diabetes care?
Herman WH, Kravitz B, Sun Y, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A436 [Abstract]
18th International Diabetes Federation Congress, Paris Prevalence and clinical significance of glutamic acid decarboxylase (GAD) antibodies in recently diagnosed type 2 diabetes in the ADOPT study cohort.
Zinman B, Kahn SE, Haffner SM, Herman W, Heise MA, O'Neill MC, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A148 [Abstract]
18th International Diabetes Federation Congress, Paris Prevalence of microalbuminuria in recently diagnosed type 2 diabetes mellitus and its relationship to non-traditional risk factors: observations from the ADOPT study
Viberti G, Freed MI, Holman R, Lachin J, Heise MA, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A326 [Abstract]
18th International Diabetes Federation Congress, Paris Lack of concordance of WHO and NCEP criteria for the diagnosis of the metabolic syndrome in recently diagnosed diabetes in North America and Europe in the ADOPT study cohort
Kahn SE, Haffner SM, Zinman B, Heise MA, O'Neill MC, Porter LE, the ADOPT Study Group
Diabetes Metabolism 2003;29:4S32 [Abstract]
18th International Diabetes Federation Congress, Paris Levels of beta-cell dysfunction and insulin resistance differ between Europeans and North Americans with recently-diagnosed diabetes in the ADOPT study
Holman RR, Kahn SE, Heise MA, Porter LE, Freed MI, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A198 [Abstract]
63rd Scientific Sessions of the American Diabetes Association, New Orleans Ethnic differences in the prevalence of the metabolic syndrome in recently diagnosed type 2 diabetes in the North American cohort of the ADOPT study
Haffner SM, Zinman B, Kahn SE, Herman WH, Heise MA, O'Neill MC, Porter LE, the ADOPT Study Group
Diabetes 2003;52:suppl:A220 [Abstract]
63rd Scientific Sessions of the American Diabetes Association, New Orleans Lack of concordance of NCEP and WHO criteria for the diagnosis of the metabolic syndrome in recently diagnosed diabetes in North America and Europe in the ADOPT study cohort
Kahn SE, Haffner SM, Zinman B, Heise MA, O'Neill MC, Porter LE, the ADOPT Study Group
Diabetes 2003;52:suppl:A222 [Abstract]
63rd Scientific Sessions of the American Diabetes Association, New Orleans Prevalence of microalbuminuria and its relationship to non-traditional risk factors in recently diagnosed type 2 diabetes mellitus: observations from the ADOPT study
Viberti G, Freed MI, Holman R, Lachin J, Heise MA, the ADOPT Study Group
Diabetes 2003;52:suppl:A190 [Abstract]
63rd Scientific Sessions of the American Diabetes Association, New Orleans Prevalence and clinical significance of glutamic acid decarboxylase (GAD) antibodies in recently diagnosed type 2 diabetes in the ADOPT study cohort
Zinman B, Kahn SE, Haffner SM, Herman W, Heise MA, O'Neill MC, the ADOPT Study Group
Diabetes 2003;52:suppl:A233 [Abstract]
63rd Scientific Sessions of the American Diabetes Association, New Orleans The ADOPT study: symptoms and health status in a recently diagnosed type 2 diabetic population
Herman W, Freed MI, Heise MA, Kravitz B, Perry A, the ADOPT Study Group
Diabetes 2003;52:suppl:A263 [Abstract]
63rd Scientific Sessions of the American Diabetes Association, New Orleans Risk of Heart Failure in Type 2 Diabetes
Coleman R, Stevens RJ, Stratton IM, Adler A, Matthews D, Holman RR
Diabetes 2003;52:Suppl 1:A217
60th Scientific Sessions of the American Diabetes Association, Glasgow Six-year results from the Early Diabetes Intervention Trial
Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V
Diabetic Medecine 2003;20:(Suppl 2):15 [Abstract]
2002
62nd Scientific Sessions of the American Diabetes Association, San Francisco Forecasting Coronary Case Fatality in Type 2 Diabetes: A UKPDS Risk Engine Equation
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Holman RR
Diabetes 2002;51:Suppl 2:A172
38th Annual Meeting of the European Association for the Study of Diabetes, Budapest The Glycaemic Optimisation Outcomes in Diabetes (GOOD) feasibility study: glucose control and weight gain in a 1 year community-based study
Potts NJ, Dudley CA, Holman RR
Diabetologia 2002;45:Suppl 2:A243 [Abstract]
38th Annual Meeting of the European Association for the Study of Diabetes, Budapest The effect of nateglinide stimulated insulin secretion on post challenge glucose and lipid metabolism in Type 2 diabetes
Mohanlal N, Holman RR
Diabetologia 2002;45:Suppl 2:A246 [Abstract]
38th Annual Meeting of the European Association for the Study of Diabetes, Budapest The Glycaemic Optimisation Outcomes in Diabetes (GOOD) feasibility study: early use of combination therapies and insulin in general practice.
Potts NJ, Dudley CA, Holman RR
Diabetologia 2002;45:Suppl 2:A265 [Abstract]
21st Joint Meeting of the British Endocrine Societies, Harrogate Diabetes and vascular risk
Rury R Holman
Endocrine Abstracts 2002;3:S14
193rd Meeting of the Society for Endocrinology and Society for Endocrinology joint Endocrinology and Diabetes Day, London The Role of Metformin
RR Holman, IM Stratton
Endocrine Abstracts 2002;4:DS8
2001
37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
Cull CA, Wright AD, Macleod KM, Holman RR
Diabetologia 2001;44:Suppl 1:A217 [Abstract]
37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow Autoantibodies to IA2ic and to Phogrin increase the prediction for insulin requirement in patients with Type 2 Diabetes
Bosi E, Locatelli M, Cull CA, Scirpoli M, Bonifacio E, Stratton IM, Holman RR, Bottazzo GF
Diabetologia 2001;44:Suppl 1:A103 [Abstract]
37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow Altered postprandial responses in type 2 diabetes
Mohanlal N, Holman RR
Diabetologia 2001;44:Suppl 1:A165 [Abstract]
37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow Calcium/calmodulin dependent Protein Kinase II genes: genomic structure and screening for variants in subjects with type 2 diabetes
Gloyn AL, Desai M, Clark A, Holman RR, Frayling TM, Hattersley AT, Ashcroft SJH
Diabetologia 2001;44:Suppl 1:A88 [Abstract]
37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow Variation at the insulin VNTR locus but not the CTLA-4 locus is associated with age of onset and need for insulin therapy in latent autoimmune diabetes in adults (LADA)
Horton VA, Stratton IM, Owen R, Holman RR, Levy JC, Clark A
Diabetologia 2001;44:Suppl 1:A75 [Abstract]
2000
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem Sulphonylurea Therapy Over Six Years Does Not Delay Progression To Diabetes
Herlihy OM, Morris RJ, Karunakaran S, Holman RR
Diabetologia 2000;43:Suppl1:A73 [Abstract]
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem Reinforced Healthy Living Advice Over Six Years Does Not Delay Progression To Diabetes
Dyson PA, Mehta Z, Hammersley M, Holman RR
Diabetologia 2000;43:Suppl1:A114 [Abstract]
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
Cull CA, Wright AD, Holman RR
Diabetologia 2000;43:Suppl 1:A40 [Abstract]
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem Butyrylcholinesterase K variant is associated with type 2 diabetes in UK caucasians
Hashim Y, Shepherd D, Wiltshire S, Clarke A, Holman RR
Diabetologia 2000;43:Suppl 1:A51 [Abstract]
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem Possible prevention of type 2 diabetes with acarbose or metformin over three years
Citroën HA, Tunbridge FKE, Holman RR
Diabetologia 2000;43:Suppl 1:A73 [Abstract]
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem ApoE ε2 and butyrylcholinesterase K variant are associated with coronary heart disease in type 2 diabetes
Horton VA, Groves CJ, Naylor M, Owen R, Wiltshire S, Stratton IM, Green F, Holman RR
Diabetologia 2000;43:Suppl 1:A86 [Abstract]
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem Standardised HbA1c measurements are essential for the management of glycaemia as a risk factor in diabetes
Manley SE, Holman RR
Diabetologia 2000;43:Suppl 1:A232 [Abstract]
60th Scientific Sessions of the American Diabetes Association, San Antonio Possible Prevention of Type 2 Diabetes with Acarbose or Metformin
Holman RR, North BV, Tunbridge FK
Diabetes 2000;40:(Suppl 1):A111 [Abstract]
1998
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Diabetes in families study: The insulin resistance syndrome segregates into 5 underlying factors in non-diabetic siblings of type 2 diabetic patients.
Morris RJ, Levy JC, Barrow BA, Ross IJ, Turner RC
Diabetologia 1998;41:Suppl 1:A70 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Insulin VNTR and HLA DRB1/DQB1 loci affect age of presentation of autoimmune diabetes in adults
Horton VA, Stratton IM, Owen RJ, Bennett ST, Todd JA, Holman RR, Turner RC
Diabetologia 1998;41:Suppl 1:A105 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Screening of SUR 1 and KIR6.2 promoters for mutations in different types of type 2 diabetes
Gloyn AL, Hashim Y, Turner RC
Diabetologia 1998;41:Suppl 1:A108 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Hepatocyte nuclear factor-4α (MODY1) gene mutations in late-onset type 2 diabetics in the UK
Shepherd DE, Hashim Y, Turner RC
Diabetologia 1998;41:Suppl 1:A111 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Paraoxonase polymorphism MET-LEU 54 is associated with fatal myocardial infarction in type 2 diabetic patients
Groves CJ, Horton VA, Ritchie A, Owen RJ, Stratton IR, Green FR, Holman RR, Turner RC
Diabetologia 1998;41:Suppl 1:A115 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Elevated proinsulin but not amyloid polypeptide accompanies declining ß-cell function in type 2 diabetes
McNamara CM, Clark A, Turner RC
Diabetologia 1998;41:Suppl 1:A169 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Hyperglycaemic siblings of type 2 diabetic patients have greater central obesity than their normoglycaemic siblings but similar physical activity indices.
Herlihy OM, Barrow BA, Levy JC, Wareham NJ, Turner RC
Diabetologia 1998;41:Suppl 1:A212 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Retinopathy in subjects with increased fasting plasma glucose levels.
Karunakaran S, Aldington S, North B, Ryder R, Holman RR
Diabetologia 1998;41:Suppl 1:A283 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Genetic predisposition to vascular complications of diabetes
Izmajlowicz ML, Groves C, Horton V, Owen R, Stratton I, Turner RC, Green FR
Diabetologia 1998;41:Suppl 1:A353 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona In normoglycaemic siblings of type 2 diabetic patients, obesity accounts for decreased insulin sensitivity but not for hypertension
Levy JC, Morris RJ, Barrow BA, Ross IJ, Turner RC
Diabetologia 1998;41:Suppl 1:A70 [Abstract]
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Hepatocyte nuclear factor 1-alpha (MODY 3) gene mutations in type 2 diabetics of different ethnicity
Hashim Y, Shepherd DE, Li J, Chan J, Turner RC
Diabetologia 1998;41:Suppl 1:A114 [Abstract]
1976
Medical Research Society Meeting 1976, A New Approach to the Treatment of Mild Diabetes
Holman RR, Turner RC
Clinical Science 1976;p18 [Abstract]
Medical Research Society Meeting 1976, Beta Cell Deficiency in Maturity Onset Diabetes
Turner RC, Holman RR, Hockaday TDR
Clinical Science 1976;p18 [Abstract]
12th Annual Meeting of the European Association for the Study of Diabetes, Helsinki A New Approach to the Treatment of Mild Diabetes
Holman RR, Turner RC
Diabetologia 1976;12:398-399 [Abstract]
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857242 Email: dtu@dtu.ox.ac.uk
